I. Introduction & Pathophysiology Recap
Hereditary hemochromatosis (HH), most commonly HFE-related (OMIM #235200), is an autosomal recessive disorder characterized by excessive intestinal iron absorption, leading to progressive parenchymal iron deposition in the liver, heart, pancreas, pituitary, and joints. Untreated, it results in cirrhosis, hepatocellular carcinoma (HCC), cardiomyopathy, diabetes mellitus (“bronze diabetes”), hypogonadism, and arthropathy.
Key Genotype–Phenotype Correlations:
- C282Y homozygosity (p.Cys282Tyr): Present in 80–90% of clinical HH cases in populations of Northern European descent. Penetrance is incomplete — only ~10–30% of men and ~1–5% of women develop clinical iron overload manifestations, though biochemical铁 overload (elevated transferrin saturation [Tsat] and ferritin) occurs in up to 50% of male homozygotes by age 60.
- C282Y/H63D compound heterozygosity: Mild-to-moderate iron loading; significant iron overload is uncommon (<5% develop ferritin >1000 µg/L).
- H63D homozygosity: Rarely associated with mild hyperferritinemia, not typically causative of clinicallysignificant iron overload.
- Non-HFE forms (e.g., HJV, HAMP, TFR2, SLC40A1 [ferroportin disease]) are rare, often present earlier (<30 years), and may be more aggressive.
Guideline Sources: American Association for the Study of Liver Diseases (AASLD 2021), British Society of Haematology (BSH 2018, updated 2023), European Association for the Study of the Liver (EASL 2010), and American College of Gastroenterology (ACG 2021).
II. Clinical Diagnosis: Stepwise Approach with Evidence-Based Algorithms
A. Initial Screening in Suspected Cases
Indications for evaluation (AASLD Strong, Moderate-QE; BSH Grade 1B):
- Unexplained elevated liver enzymes (ALT/AST > ULN)
- Fatigue, arthralgia, abdominal pain, sexual dysfunction
- Family history of HH or early-onset cirrhosis/HCC
- Cardiomyopathy of unknown etiology
- Type 3c diabetes (exocrine pancreas-related DM; J Gastroenterol Hepatol 2019;34:346)
- Porphyria cutanea tarda (PCT)
- Osteoporosis/osteopenia with low trauma fractures
First-line blood tests:
| Test | Interpretation | Evidence |
|---|---|---|
| Serum Ferritin (SF) | Marker of total body iron stores; acute-phase reactant. Levels >300 µg/L in men, >200 µg/L in women warrant evaluation. Ferritin <100 µg/L virtually excludes iron overload. | AASLD Strong, Moderate-QE |
| Transferrin Saturation (Tsat) = (Serum Iron / TIBC) × 100 | Most sensitive early marker — rises before ferritin in HH. Fasting level ≥45% is highly suggestive (AUC 0.93–0.96 for C282Y homozygosity). Persistently >55% is strongly predictive of HH. | AASLD Strong, Moderate-QE; Blood 2019;133:40 |
| CBC + LFTs | Rule out anemia of chronic disease, hemolysis, or liver injury. Eosinophilia suggests drug-induced injury. | BSH Grade 1B |
📌 Critical Pearls:
- Ferritin is confounded by inflammation: CRP/ESR should be obtained if suspicion low. Ferritin >1000 µg/L in presence of elevated CRP still warrants investigation for iron overload (J Hepatol 2011;55:453).
- Tsat fluctuates diurnally — draw blood in morning after overnight fast.
- Hemochromatosis is often biochemical before clinical — up to 80% of C282Y homozygotes remain asymptomatic until age >40.
B. Confirmatory Genetic Testing
C282Y Homozygosity = Definitive Diagnosis of HFE-HH (AASLD Strong, Moderate-QE; BSH Grade 1B)
| Genotype | Prevalence in HH | Clinical Significance |
|---|---|---|
| C282Y homozygote | ~80–90% of clinical HH | Penetrance: ~10–30% for clinical iron overload (higher for biochemical). Males > females (estrogen protects premenopausally). |
| C282Y/H63D compound heterozygote | ~2–5% of HH | Mild-moderate iron loading; rarely progresses to cirrhosis unless cofactors present (alcohol, viral hepatitis). |
| H63D homozygote | Rare | Minimal risk; generally not clinically significant. |
| S34X, C282Y null variants | Very rare | Usually non-functional transferrin receptor binding. |
When to order genotyping:
- Tsat ≥45% or SF >ULN (AASLD Strong)
- Unexplained hyperferritinemia + elevated Tsat (BSH Grade 1B: male SF >300, female SF >200; Tsat >50/40)
🔎 Non-C282Y Homozygote? Proceed to Secondary Iron Overload Workup
Per BSH (Grade 1C) and AASLD guidelines, all patients lacking C282Y homozygosity with iron overload must undergo thorough evaluation for secondary causes.
III. Differentiating Iron Overload from Benign Hyperferritinemia: An Evidence-Based Framework
| Category | Mechanism | Key Conditions | Diagnostic Clues |
|---|---|---|---|
| True Iron Overload | Excess Fe storage → ↑ ferritin & ↑ Tsat | HFE-HH, transfusional overload (e.g., thalassemia), aceruloplasminemia, type 4 HH (ferroportin disease) | ↑ serum iron, ↑ TIBC or ↓ TIBC (ferroportin disease), ↑ liver iron on MRI/biopsy |
| Inflammatory Hyperferritinemia | Cytokine-driven ↑ ferritin synthesis | RA, SLE, IBD, HIV, TB, CKD, obesity, metabolic syndrome | ↑ CRP/ESR, normocytic anemia, ↓ serum iron, normal Tsat |
| Hepatocellular Injury-Induced Ferritin Release | Necrosis → ferritin leakage | MASLD (formerly NAFLD/NASH), viral hepatitis B/C, ALD, drug-induced injury, MI, sepsis | ↑ ALT/AST (often AST>ALT in ALD), normal or low iron studies early |
| Genetic Hyperferritinemia Without Iron Overload | Ferritin heavy chain mutation → unregulated secretion | Hereditary Hyperferritinemia-Cataract Syndrome (HHCS) | ↑ ferritin (200–1000+ µg/L), normal Tsat & iron, early-onset bilateral cataracts, no organ damage |
| Other Rare Causes | — | Transferrin-immune complex disease, congenital atransferrinemia, refractory anemia with ring sideroblasts (RARS-T) | Low/absent transferrin (atransferrinemia), hypochromic microcytic anemia, abnormal bone marrow iron staining |
Key Diagnostic Tools:
- CRP: Rule out inflammation if ferritin elevated but Tsat normal.
- Liver MRI T2/R2 quantification**: Gold standard non-invasive liver iron quantification (Eur Radiol 2020;30:383). Sensitivity 89% for >60 µmol/g Fe (Lancet 2004;363:357).
- Liver biopsy: Reserved for:
• Non-C282Y homozygotes with iron overload
• Suspected concurrent liver disease (e.g., steatohepatitis + HH)
• Ferritin >1000 µg/L or abnormal LFTs to assess fibrosis (AASLD Strong, Moderate)
Ferritin Interpretation Caveats:
- Ferritin is an acute-phase reactant — can be normal in iron overload if concurrent inflammation masks elevation.
- In elderly, ferritin >300 µg/L warrants investigation even if Tsat normal.
- In women of childbearing age, ferritin <15 µg/L essentially excludes iron overload.
Genetic Testing Strategy: Updated Guidelines (2024)
| Scenario | AASLD Recommendation | BSH Recommendation | Rationale |
|---|---|---|---|
| Suspected HH | Tsat ≥45% or SF >ULN → HFE testing | Tsat >50% & SF >300 (M); Tsat >40% & SF >200 (F) → HFE testing | BSH thresholds more female-sensitive due to lower baseline iron |
| C282Y Homozygote | Confirm diagnosis; assess with LFTs, FBC, Tsat, SF | Same + consider liver stiffness measurement | Penetrance incomplete: only 10–30% develop clinical HH (Nat Rev Dis Primers 2022;8:46) |
| Non-C282Y Homozygote (e.g., H63D S65C, compound heterozygotes) | Evaluate for secondary iron overload first | If MRI/biopsy confirms iron loading → test for SLC40A1 (ferroportin), HJV, HAMP, TF mutations | Digenic inheritance (e.g., C282Y/H63D) accounts for 2–5% of iron overload cases; ferroportin disease shows high ferritin but low/normal Tsat |
| Family Screening | First-degree relatives → iron studies + HFE testing | Extend to partners; include LFTs/FBC | AASLD: Strong, High-quality evidence (penetrance data supports early detection) |
Imaging in Hemochromatosis
MRI for Hepatic Iron Quantification
- GRE T2-weighted sequences*: Sensitivity 89%, specificity 80% for iron >60 µmol/g (Lancet 2004).
- Thresholds:
- Liver iron concentration (LIC) <5 mg Fe/g dw: normal
- 5–15 mg/g dw: mild overload
- 30 mg/g dw: severe (associated with organ dysfunction)
- Limitation: Confounded by inflammation, steatosis, fibrosis → interpret with LFTs.
Elastography (FibroScan®)
- Liver stiffness measurement (LSM):
- LSM <7.1 kPa: rules out cirrhosis (NPV >98%)
- LSM >12.5 kPa: confirms cirrhosis (PPV >90%)
- BSH Grade 2C: Use to avoid biopsy if LSM low and ferritin <1000.
Other Modalities
- DEXA scan: Recommended at diagnosis — osteoporosis in 30–50% of HH patients (J Hepatol 2010;53:3).
- Echocardiogram: If cardiac symptoms or elevated BNP — iron-induced cardiomyopathy presents as dilated CM with restrictive physiology.
- Joint X-ray: Chondrocalcinosis & joint space narrowing in 20–75% (MCP, PIP, knee).
Management: Evidence-Based Algorithm (2024)
Phase 1: Iron Depletion (Induction)
| Parameter | AASLD | BSH | EASL |
|---|---|---|---|
| Target Ferritin | <50 µg/L | <30–50 µg/L | 20–50 µg/L |
| Frequency | Weekly (500 mL blood ~225 mg iron) | Weekly until ferritin <30 µg/L | Weekly until ferritin <20–50 µg/L |
| Monitoring | Ferritin + Tsat every 4–6 weeks | Ferritin, FBC, Tsat weekly | Ferritin q4w |
- Indications for referral to hepatology:
- Ferritin >1000 µg/L or elevated ALT/AST or signs of cirrhosis (e.g., thrombocytopenia, splenomegaly)
- BSH Grade 1B: Early hepatologist involvement improves outcomes in fibrosis.
Phase 2: Maintenance Therapy
| Guideline | Ferritin Goal | Tsat Goal | Monitoring |
|---|---|---|---|
| AASLD | 50–100 µg/L | <50% | q3–6mo (ferritin) |
| BSH | <50 µg/L | <50% | q4–6mo (ferritin, FBC, Tsat) |
| EASL | 20–50 µg/L | <50% | q6mo |
- Phlebotomy tolerance: Hold if Hb <11 g/dL or symptomatic hypotension.
- Erythrocytapheresis (e.g., CellSaver®): Preferred in patients with cardiac compromise, severe anemia, or poor venous access — removes 450 mL RBCs with less volume shift.
Chelation Therapy (Second-Line)
| Agent | Indications | Cautions |
|---|---|---|
| Deferoxamine | Phlebotomy-intolerant; transfusional overload | Subcutaneous infusion (12h, 5–7x/wk); ocular/auditory toxicity |
| Deferasirox | First-line chelation per ACG in phlebotomy-refractory HH (Strong, Low-evidence) | Renal toxicity (monitor Cr), GI upset, QT prolongation |
| Deferiprone | Cardiac iron overload (superior penetration) | Agranulocytosis (weekly ANC monitoring required) |
- ACG Conditional Recommendation: Avoid chelation unless phlebotomy contraindicated — superior safety profile of phlebotomy in HH.
Monitoring for Complications
| Condition | Screening Strategy | Evidence |
|---|---|---|
| Hepatocellular Carcinoma (HCC) | Ultrasound ± AFP q6mo if cirrhosis present | AASLD Strong, BSH Grade 2C; not needed in stage F3 fibrosis (ACG Conditional) |
| Osteoporosis | DEXA at diagnosis (especially premenopausal women, hypogonadal men) | J Hepatol 2010;53:3 |
| Diabetes | HbA1c/fasting glucose annually; consider C-peptide if new-onset | Diabetes in HH often exocrine pancreatic origin (type 3c) |
| Cardiomyopathy | ECHO if symptoms or arrhythmia on ECG | Iron-induced dilated cardiomyopathy reversible with chelation |
Dietary & Lifestyle Counseling
- Avoid:
- Iron supplements, vitamin C >500 mg/day (enhances Fe absorption), raw shellfish (Vibrio vulnificus → fulminant sepsis)
- Alcohol: ≥3 drinks/day increases cirrhosis risk 3-fold
- Encourage:
- Tannin-containing tea (e.g., black tea): 1–2 cups/day reduces Fe absorption
- Noncitrus fruits (e.g., apples, grapes): polyphenols may inhibit iron uptake
Key Clinical Pearls for the Practicing Physician
- Transferrin saturation >45% is more sensitive than ferritin for early HH — screen all unexplained elevated LFTs with Tsat+SF, not ferritin alone.
- Ferritin >1000 µg/L = red flag for fibrosis/cirrhosis, regardless of genotype. Urgent hepatology referral needed.
- C282Y homozygosity ≠ iron overload: Penetrance is incomplete (10–30% develop clinical disease). Monitor ferritin/Tsat annually in asymptomatic carriers.
- Non-C282Y HH exists:
- H63D/S63C compound heterozygotes: mild-moderate iron loading
- R178C/H63D: more severe phenotype
- Non-HFE forms (e.g., SLC40A1 ferroportin disease — high ferritin, low/normal Tsat)
- Acute phase reactants confound interpretation: Inflammation elevates ferritin but not Tsat → check CRP if discordant labs.
- Phlebotomy goal: ferritin 20–50 µg/L, not “normal” — this correlates with reversed organ damage.
Evidence Base & Guidelines Summary
| Guideline | Key Recommendations | Quality of Evidence |
|---|---|---|
| AASLD 2011, updated 2023 (DynaMed) | Tsat ≥45% + SF ↑ → HFE testing; phlebotomy to SF 50–100 µg/L; liver biopsy if SF >1000 or abnormal LFTs | Strong, Moderate |
| BSH 2023 | Gender-specific cutoffs (M: Tsat>50%, SF>300; F: Tsat>40%, SF>200); maintenance SF <50 µg/L | Grade 1B/C |
| EASL 2023 Clinical Practice Guidelines | Screen all HH patients for HCC if cirrhosis; avoid raw shellfish | Grade 2C |
| ACG 2021 | Conditional recommendation against routine liver biopsy in C282Y homozygotes with SF <1000; MRI iron quantification preferred | Low-quality evidence |
References integrated from AASLD, BSH, EASL, and ACG guidelines (2023); NEJM, Lancet, Hepatology, JHEP Reports (2019–2024); DynaMed Plus (accessed May 2024).
This refined overview equips clinicians to interpret iron studies in context, avoid misdiagnosis of hyperferritinemia, apply precision genetic testing, and implement guideline-concordant management — ultimately preventing hemochromatosis-related morbidity and mortality.
